APA (7th ed.) Citation

A, B., Y, F., LR, B., R, B., K, C., VC, C., . . . RT, G. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 81(Suppl 3), i1. https://doi.org/10.1093/cid/ciaf424

Chicago Style (17th ed.) Citation

A, Bhimraj, et al. "2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 81, no. Suppl 3 (2026): i1. https://doi.org/10.1093/cid/ciaf424.

MLA (9th ed.) Citation

A, Bhimraj, et al. "2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 81, no. Suppl 3, 2026, p. i1, https://doi.org/10.1093/cid/ciaf424.